C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms

Objective The objective of this study is to assess the prognostic usefulness of the Multinational Association of Supportive Care in Cancer (MASCC) risk score in association with the value of C-reactive protein (CRP) to identify high-risk patients with febrile neutropenia and hematologic neoplasms. M...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2015-04, Vol.23 (4), p.1009-1013
Main Authors: Combariza, Juan F., Lombana, Milton, Pino, Luis E., Arango, Marcos
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - adverse effects
Biomarkers
C-reactive protein
C-Reactive Protein - analysis
Cancer
Chemotherapy
Cohort Studies
Febrile Neutropenia - chemically induced
Febrile Neutropenia - mortality
Female
Health aspects
Hematologic Neoplasms - blood
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - mortality
Hematology
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Mortality
Multivariate Analysis
Neoplasms - drug therapy
Neutropenia
Nursing
Nursing Research
Oncology
Original Article
Pain Medicine
Predictive Value of Tests
Prognosis
Proteins
Rehabilitation Medicine
Retrospective Studies
Risk Assessment
Risk factors
Severity of Illness Index
Side effects
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The objective of this study is to assess the prognostic usefulness of the Multinational Association of Supportive Care in Cancer (MASCC) risk score in association with the value of C-reactive protein (CRP) to identify high-risk patients with febrile neutropenia and hematologic neoplasms. Methods A retrospective cohort study in which the MASCC score and the CRP values were used to assess the mortality risk at 30 days among patients with febrile neutropenia and hematologic malignancies was performed. Results Two hundred thiry-seven patients with febrile neutropenia were analyzed; the mortality rate within 30 days was 9 %. High-risk patients according to the MASCC score were significantly more likely to experience adverse outcomes, such as being transferred to the intensive care unit (RR 3.55; CI 95 % 2.73–6.62, p  
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-014-2454-2